Legal Representation
Attorney
John Gary Maynard, III
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 15, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 15, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 12, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 17, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 17, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 27, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 9, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 8, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 7, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 7, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 8, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 8, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 8, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 17, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Feb 17, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 17, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Dec 7, 2022 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Sep 27, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Sep 26, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 13, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Developing microbiome preparations for foods and medicines for use by mother and infant pairs; developing microbiome preparations for use in treating patients with atopic, allergic, inflammation, inflammatory conditions, infections, autoimmune, cognitive, metabolic disorders and diseases; development of microbiome preparations for pregnant women; development of microbiome preparations for the prevention and treatment of autism; development of microbiome preparations for older adults, elderly; Pharmaceutical and non-pharmaceutical product research and development; product research and development of medicines, nutritional and dietary supplements; Development of computer platforms technology for discovery and development of therapeutics for the treatment, prevention, palliation, and diagnosis of diseases; Research and development of products for the diagnosis of human disease or human health-related conditions; Research of non-pharmaceutical and pharmaceutical products for the prevention or treatment of human diseases or human health-related conditions; Development of computer platforms for discovery and development of research for therapeutics products for the reduction of risk, diagnosis, prevention, palliation, or treatment of human diseases or human health-related conditions; Medical and scientific research in the field(s) of infant gut microbiome health, maternal-infant health and wellness, infant health and wellness, preterm infant health and wellness; Research and development in the field(s) of maternal health, infant health, preterm infant health, gut health, immune health, namely, vaccine efficiency, and metabolic health; Biomedical research services related to health and clinical status of pregnant women, preterm infants, term infants, toddlers and children; Research and development of diagnostics for biological, behavioral, auditory, and pictorial health indicators; Medical and bioscience research services in the areas of the microbiome, immune system, metabolic systems of pregnant women, preterm infants, term infants, toddlers and children; Medical and bioscience research services in to the areas of the microbiome, immune system, and metabolic systems of older adults and elderly; Platform as a service (PAAS) featuring predictive, monitoring and diagnostic computer software platforms for caregivers and healthcare providers to monitor health and wellness of pregnant women, nursing mothers, caregivers, and their infants; development of consumer devices for recording and monitoring health attributes to work in conjunction with or related to live bacterial therapeutics or food products; Development of tools for measuring and tracking infant health data for purposes of evaluating effectiveness of treatment of diseases and medical conditions; Development of maternal and infant wellness tests and applications; Development of Software as a Medical Device (SaMD); Development of Machine Learning as a Medical Device (MLaMD); Development of downloadable mobile applications for monitoring, managing, and treating medical conditions and diseases
Additional Information
Design Mark
The mark consists of six gold circles and the stylized wording "INFINANT HEALTH" in black.
Color Claim
The color(s) black and gold is/are claimed as a feature of the mark.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"HEALTH"